Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline

Stock News

02/06

On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1169632829"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169632829\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169632829?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169632829","market":"other","top_or_hot":-1,"title":"Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline","media":"Stock News","content":"<p>On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-02-06 01:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"","article_id":"1169632829","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169632829","pubTimestamp":1770313654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","PSQ":"做空纳斯达克100指数ETF-ProShares","BK4588":"碎股","BK4535":"淡马锡持仓","TQQQ":"纳指三倍做多ETF","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","BK4550":"红杉资本持仓","TNA":"罗素2000指数三倍做多ETF-Direxion","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QQQ":"纳指100ETF","USAW.SI":"AMZN 3xLongSG261006","BK4007":"制药","QYLD":"纳斯达克100 Covered Call ETF-Global X","RWM":"罗素2000指数反向ETF","BK4539":"次新股","TSYW.SI":"TESLA 3xLongSG261006","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SRTY":"罗素2000指数三倍做空ETF-ProShares","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","BK4581":"高盛持仓","UWM":"罗素2000指数ETF两倍做多","QYLG":"Nasdaq 100 Covered Call & Growth ETF","BK4585":"ETF&股票定投概念","NVIW.SI":"NVDA 3xLongSG261006","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","TZA":"罗素2000指数三倍做空ETF","SQQQ":"纳指三倍做空ETF","BK1147":"投资银行业与经纪业","BK4534":"瑞士信贷持仓","IWN":"罗素2000价值股指数ETF-iShares","BK4139":"生物科技","IWO":"罗素2000成长股指数ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","TWM":"罗素2000指数两倍做空ETF","EIKN":"Eikon Therapeutics","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","QQQM":"NASDAQ100指数ETF-Invesco"},"translate_title":"Eikon Therapeutics在纳斯达克首次亮相，开盘跌幅超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RWM":1,"UWM":1,"USJW.SI":1,"GPIQ":1,"JEPQ":1,"NVIW.SI":1,"TZA":1,"TNA":1,"SRTY":1,"QQQ":1,"QQQY":1,"TSYW.SI":1,"QLD":1,"QQQM":1,"QQQE":1,"TWM":1,"USAW.SI":1,"IWO":1,"PSQ":1,"QYLD":1,"QYLG":1,"MNQmain":1,"TQQQ":1,"SQQQ":1,"QID":1,"IWN":1,"QQQJ":1,"EIKN":1},"content_text":"On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}